FPI conducts preclinical trials of drug intended to save seriously injured

14 August 2018

GMP News

Human trials of the drug being developed to save the seriously injured and to extend the “golden hour” – the time regarded as the most critical for saving lives – can begin at least in three years, according to Anatoly Kovtun, Head of the project group of the Foundation for Advanced Research Projects (FPI).

Liquid mixtures based on xenon were developed within the framework of the FPI project, which is being carried out in collaboration with the Institute of Cell Biophysics RAS from 2015. The ultimate goal of the project is to create a medicine to extend the “golden hour” by induction of an artificial hypobiosis state in human, similar to the state of hibernation in bears.

“I think that human trials can begin no earlier than three years from now. We have already assessed the effectiveness of the drug, but its safety is not yet assessed,” Mr. Kovtun said.

According to him, it is necessary to go through the entire phase of preclinical studies with testing the drug in no less than four species of animals. Previously, scientists gradually studied the effect of the drug on different groups of animals, starting from small ones: mice, rats, rabbits.

“Now we proceed to the next intermediate experiment on dwarf pigs, which have some physiological parameters that are very similar to humans, especially those of the circulatory system. This is a very reliable object for such intermediate studies. Then we will conduct studies in primates,” commented Mr. Kovtun.

Previous publication Next publication

Media Center

  • 19 September 2018

    Russia approves new state strategy for pharmaceutical industry

    A new state strategy for the development of the domestic pharmaceutical industry, known as "Strategy for the development of the pharmaceutical industry of Russia until 2030," has been recently approved by the Russian Ministry of Industry and Trade, with the aim to bring the Russian pharmaceutical production to a new level.

  • 18 September 2018

    The Ministry of Health of the Russian Federation improves patent protection law

    The Ministry of Health of Russia has published a notification on the development of amendments to Federal Law No. 61 of 12.04.2010 “On circulation of medicinal products”, designed to synchronize it with regulatory acts of the Eurasian Economic Union. The procedure for registration of the medicinal product will be corrected.

  • 17 September 2018

    GlobalData published new report on the Top 25 pharma companies

    The performance highlights of the Top 25 publicly traded global pharmaceutical companies by Market Cap (Mcap) for the quarter ended June 30, 2018 (Q2), compared to the quarter ended March 31, 2018 (Q1), have been analyzed in the latest research from GlobalData, a leading data and analytics company.

  • 14 September 2018

    US scientists conduct clinical trial of influenza vaccine with imiquimod

    A Phase 1 clinical trial examining whether a topical cream can enhance the immune response conferred by a “pre-pandemic” influenza vaccine is underway at Baylor College of Medicine in Houston (USA). Investigators are evaluating whether imiquimod cream, which is commonly used to treat genital warts and certain skin cancers, can boost the body’s immune response to an H5N1 influenza vaccine. The trial is enrolling 50 healthy adults ages 18-50 years. 

Read more